HURA News
TuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and Exposition
TuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and Exposition TuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and ExpositionPR NewswireTAMPA, Fla., Nov. 4, 2026 Presentations...
PR Newswire
TuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and Exposition
TuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and Exposition TuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and ExpositionPR NewswireTAMPA, Fla., Nov. 4, 2026 Presentations...
PR Newswire
TuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell Carcinoma TuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an...
PR Newswire
TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025 TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025PR NewswireTAMPA, Fla., Oct. 13, 2026Patent extends coverage to include bispecific/multi-specific...
PR Newswire
TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) TechnologyPR NewswireTAMPA, Fla., Oct...
PR Newswire
TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the...
PR Newswire
TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference PR Newswire TAMPA, Fla., Sept. 8, 2026 TAMPA, Fla., Sept. 8, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc...
PR Newswire
TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update PR Newswire TAMPA, Fla., Aug. 14, 2026 TAMPA, Fla., Aug. 14, 2026 /PRNewswire/ -- TuHURA Biosciences...
PR Newswire
TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference PR Newswire TAMPA, Fla., July 22, 2026 TAMPA, Fla., July 22, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or...
PR Newswire
TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting...
PR Newswire
TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update PR...
PR Newswire